Phase 1 study of fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis. J of Skin [Internet]. 2023 Mar. 13 [cited 2025 Apr. 19];7(2):s179. Available from: https://skin.dermsquared.com/skin/article/view/1997